Glaukos Corporation (GKOS)Healthcare | Medical Devices | Aliso Viejo, United States | NYSE
179.87 USD
-2.04
(-1.121%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 179.87 |
Hot Take ↕ | Aug. 22, 2026, 6:03 a.m. EDT
Glaukos is delivering on its growth promise with revenue surging nearly 50 percent year-over-year and gross margins remaining robust near 80 percent, while the balance sheet holds a fortress-like current ratio above five. The recent Q2 earnings beat and raised sales guidance provide a strong catalyst for the near term, pushing the stock well above its 50- and 200-day moving averages. However, the valuation is stretched with a forward P/E exceeding 360 and negative operating margins, preventing a top-tier long-term rating. Options activity shows significant hedging via put open interest, which may dampen immediate upside momentum despite the bullish fundamentals. This is a high-conviction growth play for investors comfortable with the lack of profitability and dividend yield. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.327614 |
| AutoARIMA | 0.327615 |
| AutoTheta | 0.333857 |
| MSTL | 0.334220 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 4.88 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.314 |
| Excess Kurtosis | -0.79 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 15.766 |
| Revenue per Share | 10.577 |
| Market Cap | 10,609,440,768 |
| Forward P/E | 356.65 |
| Beta | 0.76 |
| Profit Margins | -30.69% |
| Website | https://www.glaukos.com |
As of Aug. 22, 2026, 6:03 a.m. EDT: Speculators are positioning for volatility with heavy put open interest in the near term (September through December 2026), suggesting a floor or hedging strategy against potential pullbacks. Despite this defensive positioning, call open interest clusters at higher strikes (200-210), indicating upside targets remain in mind. Implied volatility is elevated across expirations, reflecting uncertainty surrounding the recent earnings beat and guidance revisions.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.9362427 |
| Address1 | One Glaukos Way |
| All Time High | 191.62 |
| All Time Low | 14.25 |
| Ask | 187.39 |
| Ask Size | 300 |
| Audit Risk | 1 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 605,100 |
| Average Daily Volume3 Month | 894,004 |
| Average Volume | 894,004 |
| Average Volume10Days | 605,100 |
| Beta | 0.762 |
| Bid | 170.05 |
| Bid Size | 300 |
| Board Risk | 8 |
| Book Value | 11.595 |
| City | Aliso Viejo |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 179.87 |
| Current Ratio | 5.04 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 182.225 |
| Day Low | 177.77 |
| Debt To Equity | 15.766 |
| Display Name | Glaukos |
| Earnings Call Timestamp End | 1,785,357,000 |
| Earnings Call Timestamp Start | 1,785,357,000 |
| Earnings Timestamp | 1,785,355,200 |
| Earnings Timestamp End | 1,793,217,600 |
| Earnings Timestamp Start | 1,793,217,600 |
| Ebitda | -37,025,000 |
| Ebitda Margins | -0.06042 |
| Enterprise To Ebitda | -281.588 |
| Enterprise To Revenue | 17.012 |
| Enterprise Value | 10,425,782,272 |
| Eps Current Year | -0.29057 |
| Eps Forward | 0.50433 |
| Eps Trailing Twelve Months | -3.24 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 949 367 9984 |
| Fifty Day Average | 161.2824 |
| Fifty Day Average Change | 18.5876 |
| Fifty Day Average Change Percent | 0.11524879 |
| Fifty Two Week Change Percent | 93.62427 |
| Fifty Two Week High | 191.62 |
| Fifty Two Week High Change | -11.75 |
| Fifty Two Week High Change Percent | -0.06131928 |
| Fifty Two Week Low | 73.16 |
| Fifty Two Week Low Change | 106.70999 |
| Fifty Two Week Low Change Percent | 1.4585837 |
| Fifty Two Week Range | 73.16 - 191.62 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,435,239,000,000 |
| Float Shares | 56,810,530 |
| Forward Eps | 0.50433 |
| Forward P E | 356.6514 |
| Free Cashflow | 15,456,250 |
| Full Exchange Name | NYSE |
| Full Time Employees | 1,094 |
| Fullday Change | -2.04001 |
| Fullday Change Percent | -1.12144 |
| Fullday Price | 179.87 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.79121 |
| Gross Profits | 484,881,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03605 |
| Held Percent Institutions | 1.05462 |
| Implied Shares Outstanding | 58,983,937 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. |
| Long Name | Glaukos Corporation |
| Market | us_market |
| Market Cap | 10,609,440,768 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_3131592 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -188,048,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,729,767,979 |
| Number Of Analyst Opinions | 13 |
| Open | 181.1 |
| Operating Cashflow | -950,000 |
| Operating Margins | -0.08495 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 949 367 9600 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 179.87 |
| Post Market Time | 1,787,961,344 |
| Previous Close | 181.91 |
| Price Eps Current Year | -619.02466 |
| Price Hint | 2 |
| Price To Book | 15.51272 |
| Price To Sales Trailing12 Months | 17.311954 |
| Profit Margins | -0.30685 |
| Quick Ratio | 4.155 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.35714 |
| Region | US |
| Regular Market Change | -2.04001 |
| Regular Market Change Percent | -1.12144 |
| Regular Market Day High | 182.225 |
| Regular Market Day Low | 177.77 |
| Regular Market Day Range | 177.77 - 182.225 |
| Regular Market Open | 181.1 |
| Regular Market Previous Close | 181.91 |
| Regular Market Price | 179.87 |
| Regular Market Time | 1,787,947,202 |
| Regular Market Volume | 551,891 |
| Return On Assets | -0.051760003 |
| Return On Equity | -0.25981 |
| Revenue Growth | 0.495 |
| Revenue Per Share | 10.577 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 58,983,937 |
| Shares Percent Shares Out | 0.067 |
| Shares Short | 3,951,091 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,703,342 |
| Short Name | Glaukos Corporation |
| Short Percent Of Float | 0.081099994 |
| Short Ratio | 4.59 |
| Source Interval | 15 |
| State | CA |
| Symbol | GKOS |
| Target High Price | 225.0 |
| Target Low Price | 172.0 |
| Target Mean Price | 197.15385 |
| Target Median Price | 195.0 |
| Total Cash | 286,225,984 |
| Total Cash Per Share | 4.855 |
| Total Debt | 107,604,000 |
| Total Revenue | 612,838,976 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.24 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 126.67795 |
| Two Hundred Day Average Change | 53.192047 |
| Two Hundred Day Average Change Percent | 0.41989982 |
| Type Disp | Equity |
| Volume | 551,891 |
| Website | https://www.glaukos.com |
| Zip | 92,656 |